
Friday, June 06, 2025 1:30:58 PM
Current process:
- surgery lysate to load tumor antigens onto DCs
- highly personalized but requires surgery
Emerging library and tech:
- Dr Ashkan previously said the UK did the whole genome sequencing of 403 glioma tumors, but actually part of of the Genomics England's 100,000 Genomes Project that sequenced 100,000 genomes from "rare conditions or cancer"
- June 2023 Marnix Bosch talked about proteomics on the tumor lysate, "found... 25,000 MHC class 1 associated peptides... almost 13,000 class 2 associated peptides... 400 different tumor-associated peptides... all presented on the dendritic cells... to the immune system"
- Use liquid biopsy (blood draws) to obtain fragments of DNA shed by tumor cells, get biomarkers
What if the NWBO Franchise includes this:
- allogeneic vaccines made from tumor cells of donors (not patients), mass production and storage for off-the-shelf
- that becomes a library or a menu of vaccine components
- for which oncologists or Franchisee members can select antigens
- would then be loaded onto partially matured DCs from a patient’s apheresis
- would create a semi-personalized DCVax-L vaccine
- that is injected into the cancer patient
- and this version still retains all the benefits of the original DCVax-L (ie efficacy, non-toxic, immune memory)
- but this time more quickly, scalable, low cost, and without surgery

Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM